Imlifidase: First Approval.

Al-Salama, Zaina T

Al-Salama, Zaina T.

Affiliation

Al-Salama ZT; Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs ; 80(17): 1859-1864, 2020 Nov.

Article in En | MEDLINE | ID: mdl-33058042

Subject(s)

Anti-Glomerular Basement Membrane Disease/drug therapy; Bacterial Proteins/therapeutic use; Drug Approval; Graft Rejection/drug therapy; Guillain-Barre Syndrome/drug therapy; Administration, Intravenous; Animals; Anti-Glomerular Basement Membrane Disease/immunology; Bacterial Proteins/pharmacology; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Desensitization, Immunologic/methods; Disease Models, Animal; Drug Evaluation, Preclinical; European Union; Guillain-Barre Syndrome/immunology; HLA Antigens/immunology; Humans; Immunoglobulin G/immunology; Immunoglobulin G/metabolism; Kidney Failure, Chronic/surgery; Kidney Transplantation/adverse effects; Randomized Controlled Trials as Topic; Rare Diseases/drug therapy; Rare Diseases/immunology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Bacterial Proteins / Drug Approval / Anti-Glomerular Basement Membrane Disease / Guillain-Barre Syndrome / Graft Rejection Type of study: Clinical_trials Language: En Journal: Drugs Year: 2020 Type: Article Affiliation country: New Zealand

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google